A Study to Evaluate Circulating Cell Free Tumor DNA as a Biomarker in Sarcoma


About this study

The purpose of this study is to determine the feasibility of ctDNA detection in patients with advanced translocation-associated sarcomas.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18 years old and older.
  • Advanced or metastatic bone or soft tissue sarcoma with a known translocation.
  • Evidence of disease progression or recurrence prior to initiation of systemic therapy.
  • No systemic therapy or major surgery within the past 30 days.
  • Willingness to provide blood and urine samples.
  • The absence of a second active malignancy.
  • An understanding of the protocol and its requirements, risks and discomforts.
  • Ability and willingness to sign an informed consent.

Exclusion Criteria

  • Pregnancy or lactation.
  • Inability to understand the informed consent.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Brittany Siontis, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


More information


Publications are currently not available

Mayo Clinic Footer